RxDoctor Payments Data

Stewart Frank, MD

Cardiovascular Disease · San Diego, CANPI 1417051558

Payments from drug & device makers

$3,465in general payments, 2019–2025

Across 157 payments — averaging $22.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$536
  • Novartis$394
  • AstraZeneca$340
  • Novo Nordisk$279
  • Johnson & Johnson$226
  • Lilly USA, LLC$203
  • plus $1K from 28 others

What the payments were for

  • Food & beverage$3,44099%
  • Education$251%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,465 in reported general payments places this provider in the 55th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$75,056
Medicare patients
248
Services billed
1,031

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban127$128,548
GenvoyaElviteg/Cob/Emtri/Tenof Alafen12$47,006
JanuviaSitagliptin Phosphate21$32,645
JardianceEmpagliflozin23$21,531
TrulicityDulaglutide13$18,279
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$12,990
MyrbetriqMirabegron12$8,063
Losartan Potassium504$5,737
Levothyroxine Sodium362$4,855
Rosuvastatin Calcium297$4,377
Atorvastatin Calcium317$2,952
Ezetimibe71$2,040
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen114$2,027
Carvedilol213$1,951
Omeprazole171$1,850

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$179$128,548127 claims
GileadGenvoya$180$47,00612 claims
MerckJanuvia$24$32,64521 claims
Boehringer IngelheimJardiance$49$21,53123 claims
Lilly USA, LLCTrulicity$203$18,27913 claims
GSKTrelegy Ellipta$155$12,99017 claims
AbbVieSynthroid$536$95625 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in San Diego

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →